Ranolazine and Ivabradine: Two different modalities to act against ischemic heart disease

Therapeutic Advances in Cardiovascular Disease

Volumn 10, Issue 2, 2016, Pages 98-102

  Cacciapuoti, Federico ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

chronic stable angina; conventional antianginal drugs; ivabradine; ranolazine

Indexed keywords

IVABRADINE; PLACEBO; RANOLAZINE; BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT;

ANGINA PECTORIS; ARTHRALGIA; BACKACHE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BLOOD FLOW; DIASTOLE; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; EXERCISE; HEADACHE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART MUSCLE POTENTIAL; HEART MUSCLE RELAXATION; HEART RATE; HUMAN; ISCHEMIC HEART DISEASE; MONOTHERAPY; MUSCLE CRAMP; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINUS NODE; STABLE ANGINA PECTORIS; SYNDROME X; ANGINA, STABLE; COMPARATIVE STUDY; DRUG EFFECTS; MYOCARDIAL ISCHEMIA; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY;

ANGINA, STABLE; BENZAZEPINES; CARDIOVASCULAR AGENTS; HEART RATE; HUMANS; MYOCARDIAL ISCHEMIA; OXYGEN CONSUMPTION; RANOLAZINE;

EID: 84963549081     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944716636042     Document Type: Review

References (41)

1. Abrams J., (2005) Clinical practice. Chronic stable angina. N Engl J Med 352: 2524-2533.
2. Amonova E., Andrejev E., Zaderey I., Rudenko U., Ceconi C., Ferrari R., (2011) Efficacy of ivabradine in combination with beta-blocker versus uptitration of beta-blocker in patients with stable angina. Cardiovasc Drugs Ther 25: 531-537.
3. Belardinelli L., Shyrock J., Fraser H., (2006a) Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 92 (Sppl.): iv6-iv14.
4. Belardinelli L., Shyrok J., Fraser H., (2006b) The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J 8 (Suppl.): A10-A13.
5. f inhibitor in stable angina. A randomized double-blind, multicentered placebo-controlled trial. Circulation 107: 817-823.
6. Chaitman B., Pepine C., Parker J., Skopol J., Chumakova G., Kurch J., et al. (2004a) Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. J Am Med Assoc 291: 309-316.
7. Chaitman B., Skettino S., Parker J., Hanley P., Meluzin J., Kuch J., et al. (2004b) Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 43: 1375-1382.
8. Chaturvedi A., Singh Y., Chaturvedi H., Thawani V., Singla S., Parihar D., (2013) Comparison of the efficacy and tolerability of ivabradine and ranolazine in patients with chronic angina pectoris. J Pharmacol Pharmacother 4: 33-38.
9. + channels in pancreatic α-cells has antidiabetic effects. Diabetes 63: 3545-3556.
10. Di Francesco D., Camm J., (2002) Current-dependent block of rabbit sino-atrial node if channels by Ivabradine. J Gen Physiol 120: 1-13.
11. Dyer A., Perki V., Stamler J., Paul O., Shekelle R., Berkson D., et al. (1980) Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 112: 736-749.
12. Eckel R., Henry R., Yue P., Dhalla A., Wang P., Jachelson P., et al. (2015) Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes. Diabetes Care 38: 1189-1196.
13. European Medicines Agency (2008) CHMP assessment report for Latixa. Evaluation of Medicines for Human Use Doc. Ref. EMRA/CHMP/30876/2008. London: European Medicines Agency.
14. f current inhibitor, ivabradine, improves diastolic function and attenuates cardiac tissue hypoxia. J Cardiovasc Pharmacol 59: 260-267.
15. Fox K., Ford I., Steg P., Tardif J., Tendera M., Ferrari R., for the SIGNIFY Investigators (2014) Ivabradine in stable coronary artery disease without heart failure. N Engl J Med 371: 1091-1099.
16. Fox K., Ford I., Steg P., Tendera M., Robertson M., Ferrari R., and BEAUTIFUL Investigators (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet 372: 817-821.
17. Hayashida W., van Eyl C., Rousseau M., Pouleur H., (1994) Effects of ranolazine on ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drug Ther 8: 74-77.
18. Kachler J., Meinertz T., and REDUCTION Study Group (2009) Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study. Am Heart J 158: 51-57.
19. Lanza G., Crea F., (2010) Primary coronary microvascular dysfunction: clinical presentation, pathophysiology and management. Circulation 121: 2317-2325.
20. f current inhibitor ivabradine in patients with chronic stable angina. A one-year randomized, double blind, multicenter trial. Eur Heart J 25 (Suppl.): 76.
21. Marquis-Gravel G., Tardif J., (2008) Ivabradine: the evidence of its therapeutic impact in angina. Core Evid 3: 1-12.
22. Morrow D., Scirica B., Karwatowska-Prokopczk E., Skene A., McCabe C., Brauwald E., (2009) Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes (MERLIN)-TIMI 36 Trial. Circulation 119: 2032-2039.
23. Ning Y., Zhen W., Fu Z., Jiang J., Liu D., Belardinelli L., et al. (2011) Ranolazine increases β-cell survival and improves glucose homeostasis in low-dose streptozocin-induced diabetes in mice. Pharmacol Exp Ther 337: 50-58.
24. Pagidipati N., Gaziano T., (2013) Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. Circulation 127: 749-756.
25. Pepine C., Wolff A., (1999) A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study group. Am J Cardiol 84: 46-50.
26. Riccioni G., (2010) Ivabradine: from molecular basis to clinical effectiveness. Adv Ther 27: 160-167.
27. Riccioni G., (2012) Ivabradine: an intelligent drug for the treatment of ischemic heart disease. Molecules 17: 13592-13604.
28. Riccioni G., (2013) Ivabradine: the hope for a good treatment of ischemic heart disease. Curr Med Chem 20: 1817-1823.
29. Riccioni G., Vitulano N., D'Orazio N., (2009) Ivabradine: beyond heart rate control. Adv Ther 26: 12-24.
30. Rich M., Crager M., McKay C., (2007) Safety and efficacy of extended-release ranolazine in stable ischemic heart disease. Am J Gen Cardiol 16: 216-221.
31. Ruzyllo W., Tendera M., Fox I., Fox K., (2007) Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3 months randomized, double-blind, multicenter, noninferiority trial. Drugs 67: 393-405.
32. Simon I., Ghaleh B., Guidicelli, Berdeux A., (1995) Coronary and hemodynamic effects of S16257, a new bradycardic agent in resting and exercising conscious dogs. J Pharmacol Exp Ther 275: 659-666.
33. Song Y., Shryock J., Wu L., Belardinelli L., (2004) Antagonism of Ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 44: 192-199.
34. Stone P., Gratsianky N., Blokhin A., Huang I., Meng L., on behalf of the ERICA Investigators (2006) Antianginal efficacy of Ranolazine when added to treatment with Amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) Trial. J Am Coll Cardiol 48: 566-575.
35. Swedberg K., Komajda M., Bohm M., Borer J., Ford I., Dubost-Brama A., et al. on behalf of the SHIFT Investigators (2010) Ivabradine and outcomes in chronic heart failure (SHIFT) a randomized placebo-controlled study. Lancet 376: 875-885.
36. f inhibitor compared to atenolol in patients with chronic stable angina. Eur Heart J 26: 2529-2536.
37. Tardif J., Ponikowski P., Kakan T., for the ASSOCIATE study investigators (2013) Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. Int J Cardiol 3: 789-794.
38. Thollon C., Bidouard J., Cambarrat C., Lesage L., Reure H., Delescluse I., (1997) Stereospecific in vitro and in vivo effects of the new sinus inhibitor (+)-S 16257. Eur J Pharmacol 339: 43-51.
39. Timmis A., Chaitman B., Crager M., (2006) Effects of ranolazine on exercise tolerance and Hb1c in patients with chronic angina and diabetes. Eur Heart J 27: 42-48.
40. Villano A., Di Franco A., Nerla R., Sistito A., Tarzia P., Lamendola P., et al. (2013) Effects of Ivabradine and Ranolazine in patients with microvascular angina pectoris. Am J Cardiol 112: 8-13.
41. Weisz G., Genereux P., Iniguez A., Zurakowski A., Shecter M., Alexander K., et al. for the RIVER-PCI Investigators (2016) Ranolazine in patients with incomplete revascularization after percutaneous coronary intervention (RIVER-PCI) a multicenter, randomized, double-blind, placebo, controlled trial. Lancet 387: 136-145.